"Would our drug, if successful, take some market share from the drug, Entresto ... or other ACE inhibitor drugs,...?" 

What apabetalone modified risk factors are you suggesting overlap with Entresto or ACE inhibitors? And are any of these being tested in BETonMACE?

In response to Golfyeti for SGLT2 inhibitors, I think we need to see how much apabetalone affects glucose and insulin measures in the diabetics in BETonMACE before we jump to conclusions that apabetalone may replace other currently approved drugs that lower glucose, increase insulin secretion or improve insulin sensitivity. SGLT2 inhibitors and GLP-1R agonists do offer some MACE reduction in addition to glucose control, but until we see BETonMACE data it is premature to assume too much.

BearDownAZ